Why the study?
Microvascular dysfunction plays a key role in patients with angina and nonobstructive coronary artery disease, prompting investigation into the impact of ranolazine in this population.
Does ranolazine improve angina frequency in patients with angina and nonobstructive coronary artery disease?
Does ranolazine improve angina frequency in patients with angina and nonobstructive coronary artery disease?
In a pilot RCT of patients with angina and nonobstructive CAD, ranolazine did not improve angina frequency, invasive microvascular function, or exercise capacity compared to placebo at 12 weeks.
No takes yet. Share an insight, caveat, or question.
Ranolazine confers no symptomatic or microvascular benefit in this pilot RCT; leaves open whether targeted therapy improves outcomes in angina with nonobstructive CAD.
Koh et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: